Blog
13 February 2026
Rapid Advances in Litifilimab: Insights from LILAC to AMETHYST in CLE
Explore rapid advances in litifilimab for cutaneous lupus erythematosus (CLE) from the LILAC study to the AMETHYST program and its...
Read more
Red Light PDT: Establishing New Standards for Treating Superficial BCC
Discover how red light PDT with 10% ALA gel is setting new standards in treating superficial BCC, backed by robust...
12 02 2026
Read more
FDA Revamps iPLEDGE REMS: Key Changes for Pregnancy Testing and Prescriptions
Discover the FDA's key changes to the iPLEDGE REMS for isotretinoin. Learn how new pregnancy testing and prescription guidelines will...
11 02 2026
Read more
New Phase 3 Results Elevate Oral TYK2 Inhibitors in Psoriasis Treatment
Discover how new Phase 3 results for oral TYK2 inhibitors, like zasocitinib, are transforming psoriasis treatment and challenging traditional biologic...
10 02 2026
Read more
Revolutionizing Non-Surgical Treatment for Superficial BCC with Red Light PDT
Discover how red light photodynamic therapy (PDT) is revolutionizing non-surgical treatment for superficial BCC, offering new hope for patients. Read...
10 02 2026
Read more
Innovative Treatment Strategies for Inflammatory Skin Diseases Explored
Discover innovative treatment strategies for inflammatory skin diseases like atopic dermatitis, psoriasis, and hidradenitis suppurativa in our latest expert interview.
9 02 2026
Read more
Transforming Skin Health: The Impact of GLP-1 Receptor Agonists
Discover how GLP-1 receptor agonists are revolutionizing skin health, enhancing dermatology practices, and transforming patient outcomes in aesthetic care.
8 02 2026
Read more
UCB Reveals 3-Year BE HEARD Results for Bimekizumab in HS Treatment
Discover UCB's groundbreaking three-year results for bimekizumab in hidradenitis suppurativa treatment, showcasing sustained efficacy and reduced disease severity.
7 02 2026
Read more
Sagimet and Ascletis Reveal Promising Long-Term Data for Denifanstat in Acne
Discover Sagimet and Ascletis's latest 52-week data on denifanstat, a groundbreaking treatment for moderate to severe acne. Learn about its...
6 02 2026
Read more